Tech Company Financing Transactions
Abselion Funding Round
M Ventures, BGF Ventures and BioProcess360 participated in a $8.4 million Series A funding round for Abselion. The funding round closed on 12/9/2024.
Transaction Overview
Company Name
Announced On
12/9/2024
Transaction Type
Venture Equity
Amount
$8,400,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to drive the commercialisation and expand the capabilities of its Amperia system.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Unit 1, Cambridge House, Oakington Road
Cambridge, CB3 0QH
UK
Cambridge, CB3 0QH
UK
Phone
Undisclosed
Website
Email Address
Overview
Abselion started in 2018, at that time under the name HexagonFab, in a small corner of a laboratory at the University of Cambridge. We set out with the humble goal to make protein research simpler. Scientists should be able to pursue their passion for discovery and innovation, rather than spend their valuable time with tedious, manual tasks. With RED we had access to the ideal technology to create this product. A product that is so compact that it could fit on every bench, and so affordable that it is accessible to everyone. Over the years we have designed, built and tested our first product Amperia and we're proud to introduce it to the world.?
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Simon Douglas
Chief Executive Officer
Ruizhi Wang
Chief Scientific Officer
Paolo Romele
Browse more venture capital transactions:
Prev: 12/9/2024: Cyder venture capital transaction
Next: 12/9/2024: Pixxel venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs